G1 Therapeutics to Participate in Two August Investor Conferences
July 31 2023 - 2:30PM
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology
company, today announced that it will participate in two August
investor conferences.
- On Monday August 7, 2023, G1’s Chief Executive Officer Jack
Bailey and other members of G1’s Executive Team will participate in
the 2023 BTIG Virtual Biotechnology Conference. BTIG-hosted events
are intended for prospective and existing BTIG clients only. To
listen to the live event, please contact your BTIG
representative.
- On Wednesday August 9, 2023, the G1 team will also participate
in one-on-one meetings with institutional investors during the 2023
Wedbush PacGrow Healthcare Conference in New York City. If
interested in a meeting, please contact your Wedbush PacGrow
representative.
About G1 TherapeuticsG1 Therapeutics, Inc. is a
commercial-stage biopharmaceutical company focused on the
development and commercialization of next generation therapies that
improve the lives of those affected by cancer, including the
Company’s first commercial product, COSELA® (trilaciclib). G1 has a
deep clinical pipeline and is executing a development plan
evaluating trilaciclib in a variety of solid tumors, including
breast, lung, and bladder cancers. G1 Therapeutics is based in
Research Triangle Park, N.C. For additional information, please
visit www.g1therapeutics.com and follow us on Twitter
@G1Therapeutics.
G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and
the COSELA logo are trademarks of G1 Therapeutics, Inc
Contacts:Will RobertsCommunications OfficerVice
President, Investor Relations & Corporate
Communications919-907-1944 wroberts@g1therapeutics.com
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Apr 2024 to May 2024
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From May 2023 to May 2024